A specific batch of the medication Xanax was recalled nationwide due to potential to cause adverse health effects. U.S. Food and Drug Administration officials announced the voluntary recall of Xanax XR, also known as alprazolam, distributed by Viatris Specialty, a limited liability company in West Virginia. According to Viatris, the recall is specific to one lot of one strength of the brand product only. The vast majority of patients in the U.S. are dispensed generic alprazolam, which this recall does not affect.
Xanax is one of the most widely prescribed medications to treat generalized anxiety and panic disorders. Addiction experts note it is considered a highly addictive substance given its psychodynamic properties that create feelings of euphoria. The drug is generally safe and helpful when used as directed, with intended effect lasting up to six hours.
Recall Details and Classification
The Xanax tablets were placed under a Class II recall because the product failed dissolution specifications, meaning it failed to dissolve at a standard rate. Class II classification means use or exposure to the product may cause temporary or medically reversible adverse health consequences. The recalled product is Xanax XR, extended-release tablets distributed between August 27, 2024, and May 29, 2025. The tablets are 3 milligrams in bottles of 60 pills. The product code information is “Lot #8177156” with an expiration date of February 28, 2027.
No illnesses or injuries have been reported in connection with the withdrawn pills. The Xanax tablets were sold nationwide. FDA officials stated that unless otherwise directed, patients and consumers can continue using the medicine. Wholesalers and retailers have been provided instructions on how to return the product. FDA guidance states that in some instances, stopping medicine may be more harmful to health than continuing to take the recalled medicine.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.arcamax.com/newsheadlines/s-4072361